W M Linehan

List of Publications by Year
in descending order

104 papers	23,029 citations	13865 67 h-index	32842 100 g-index
106 all docs	106 docs citations	106 times ranked	12154 citing authors

#	Article	IF	Citations
1	A Progress Report on the Treatment of 157 Patients with Advanced Cancer Using Lymphokine-Activated Killer Cells and Interleukin-2 or High-Dose Interleukin-2 Alone. New England Journal of Medicine, 1987, 316, 889-897.	27.0	2,695
2	Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nature Genetics, 1997, 16, 68-73.	21.4	1,461
3	Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma.. Proceedings of the National Academy of Sciences of the United States of America, 1994, 91, 9700-9704.	7.1	1,382
4	Regression of Metastatic Renal-Cell Carcinoma after Nonmyeloablative Allogeneic Peripheral-Blood Stem-Cell Transplantation. New England Journal of Medicine, 2000, 343, 750-758.	27.0	977
5	Experience with the Use of High-Dose Interleukin-2 in the Treatment of 652 Cancer Patients. Annals of Surgery, 1989, 210, 474-485.	4.2	917
6	Inhibition of transcription elongation by the VHL tumor suppressor protein. Science, 1995, 269, 1402-1406.	12.6	557
7	Recent Advances in Genetics, Diagnosis, Localization, and Treatment of Pheochromocytoma. Annals of Internal Medicine, 2001, 134, 315.	3.9	512
8	Post-transcriptional regulation of vascular endothelial growth factor mRNA by the product of the VHL tumor suppressor gene.. Proceedings of the National Academy of Sciences of the United States of America, 1996, 93, 10589-10594.	7.1	497
9	von Hippel-Lindau disease: genetic, clinical, and imaging features.. Radiology, 1995, 194, 629-642.	7.3	494
10	Novel mutations of the MET proto-oncogene in papillary renal carcinomas. Oncogene, 1999, 18, 2343-2350.	5.9	487
11	The von Hippel-Lindau tumor-suppressor gene product forms a stable complex with human CUL-2, a member of the Cdc53 family ofâ€‰proteins. Proceedings of the National Academy of Sciences of the United States of America, 1997, 94, 2156-2161.	7.1	464
12	Improved detection of germline mutations in the von Hippel-Lindau disease tumor suppressor gene. Human Mutation, 1998, 12, 417-423.	2.5	452
13	Folliculin encoded by the BHD gene interacts with a binding protein, FNIP1, and AMPK, and is involved in AMPK and mTOR signaling. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 15552-15557.	7.1	427
14	BHD mutations, clinical and molecular genetic investigations of Birt-Hogg-Dube syndrome: a new series of 50 families and a review of published reports. Journal of Medical Genetics, 2008, 45, 321-331.	3.2	420
15	Immunotherapy of patients with advanced cancer using tumor-infiltrating lymphocytes and recombinant interleukin-2: a pilot study.. Journal of Clinical Oncology, 1988, 6, 839-853.	1.6	403
16	Combination therapy with interleukin-2 and alpha-interferon for the treatment of patients with advanced cancer.. Journal of Clinical Oncology, 1989, 7, 1863-1874.	1.6	386
17	Birt-Hogg-DubÃ© Syndrome, a Genodermatosis Associated with Spontaneous Pneumothorax and Kidney Neoplasia, Maps to Chromosome 17p11.2. American Journal of Human Genetics, 2001, 69, 876-882.	6.2	355
18	Plasma Normetanephrine and Metanephrine for Detecting Pheochromocytoma in von Hippelâ€“Lindau Disease and Multiple Endocrine Neoplasia Type 2. New England Journal of Medicine, 1999, 340, 1872-1879.	27.0	335

#	Article	IF	Citations
19	Defective placental vasculogenesis causes embryonic lethality in VHL-deficient mice. Proceedings of the National Academy of Sciences of the United States of America, 1997, 94, 9102-9107.	7.1	319
20	Fusion of splicing factor genes PSF and NonO (p54nrb) to the TFE3 gene in papillary renal cell carcinoma. Oncogene, 1997, 15, 2233-2239.	5.9	298
21	Trisomy 7-harbouring non-random duplication of the mutant MET allele in hereditary papillary renal carcinomas. Nature Genetics, 1998, 20, 66-69.	21.4	291
22	Hereditary Papillary Renal Cell Carcinoma. Journal of Urology, 1994, 151, 561-566.	0.4	289
23	Small (< or = 3-cm) renal masses: detection with CT versus US and pathologic correlation.. Radiology, 1996, 198, 785-788.	7.3	286
24	Pheochromocytomas in von Hippel-Lindau Syndrome and Multiple Endocrine Neoplasia Type 2 Display Distinct Biochemical and Clinical Phenotypes. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 1999-2008.	3.6	262
25	Novel mutations in FH and expansion of the spectrum of phenotypes expressed in families with hereditary leiomyomatosis and renal cell cancer. Journal of Medical Genetics, 2005, 43, 18-27.	3.2	261
26	The t(X;1)(p11.2;q21.2) translocation in papillary renal cell carcinoma fuses a novel gene PRCC to the TFE3 transcription factor gene. Human Molecular Genetics, 1996, 5, 1333-1338.	2.9	245
27	Multiple Neuroendocrine Tumors of the Pancreas in von Hippel-Lindau Disease Patients. American Journal of Pathology, 1998, 153, 223-231.	3.8	243
28	Hereditary and Sporadic Papillary Renal Carcinomas with c-met Mutations Share a Distinct Morphological Phenotype. American Journal of Pathology, 1999, 155, 517-526.	3.8	243
29	CLINICAL AND GENETIC CHARACTERIZATION OF PHEOCHROMOCYTOMA IN VON HIPPEL-LINDAU FAMILIES: COMPARISON WITH SPORADIC PHEOCHROMOCYTOMA GIVES INSIGHT INTO NATURAL HISTORY OF PHEOCHROMOCYTOMA. Journal of Urology, 1999, 162, 659-664.	0.4	233
30	Allelic loss on chromosome 8p12-21 in microdissected prostatic intraepithelial neoplasia. Cancer Research, 1995, 55, 2959-62.	0.9	230
31	RENAL CANCER IN FAMILIES WITH HEREDITARY RENAL CANCER: PROSPECTIVE ANALYSIS OF A TUMOR SIZE THRESHOLD FOR RENAL PARENCHYMAL SPARING SURGERY. Journal of Urology, 1999, 161, 1475-1479.	0.4	229
32	Kidney-Targeted Birt-Hogg-Dube Gene Inactivation in a Mouse Model: Erk1/2 and Akt-mTOR Activation, Cell Hyperproliferation, and Polycystic Kidneys. Journal of the National Cancer Institute, 2008, 100, 140-154.	6.3	223
33	Identification of the von Hippel-Lindau (VHL) gene. Its role in renal cancer. JAMA - Journal of the American Medical Association, 1995, 273, 564-570.	7.4	213
34	Collecting duct carcinoma of the kidney. Human Pathology, 1990, 21, 449-456.	2.0	211
35	Endolymphatic sac tumors. A source of morbid hearing loss in von Hippel-Lindau disease. JAMA - Journal of the American Medical Association, 1997, 277, 1461-1466.	7.4	204
36	Homozygous loss of BHD causes early embryonic lethality and kidney tumor development with activation of mTORC1 and mTORC2. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 18722-18727.	7.1	203

#	Article	IF	Citations
37	Genetic basis of kidney cancer: Role of genomics for the development of disease-based therapeutics. Genome Research, 2012, 22, 2089-2100.	5.5	202
38	A microdissection technique for archival DNA analysis of specific cell populations in lesions < 1 mm in size. American Journal of Pathology, 1995, 146, 620-5.	3.8	198
39	Pancreatic neuroendocrine tumors associated with von Hippel Lindau disease: Diagnostic and management recommendations. Surgery, 1998, 124, 1153-1159.	1.9	197
40	The von Hippel-Lindau Tumor Suppressor Gene Inhibits Hepatocyte Growth Factor/Scatter Factor-Induced Invasion and Branching Morphogenesis in Renal Carcinoma Cells. Molecular and Cellular Biology, 1999, 19, 5902-5912.	2.3	194
41	Evidence of Independent Origin of Multiple Tumors From Patients With Prostate Cancer. Journal of the National Cancer Institute, 1998, 90, 233-237.	6.3	191
42	Analysis of 99 microdissected prostate carcinomas reveals a high frequency of allelic loss on chromosome 8p12-21. Cancer Research, 1996, 56, 2411-6.	0.9	187
43	Laparoscopic adrenalectomy: A new standard of care. Urology, 1997, 49, 673-678.	1.0	176
44	von Hippel-Lindau gene deletion detected in the stromal cell component of a cerebellar hemangioblastoma associated with von Hippel-Lindau disease. Human Pathology, 1997, 28, 540-543.	2.0	176
45	Catecholamine metabolomic and secretory phenotypes in phaeochromocytoma. Endocrine-Related Cancer, 2010, 18, 97-111.	3.1	169
46	Mosaicism in von Hippelâ€“Lindau Disease: Lessons from Kindreds with Germline Mutations Identified in Offspring with Mosaic Parents. American Journal of Human Genetics, 2000, 66, 84-91.	6.2	165
47	Predicting survival in patients with metastatic kidney cancer by gene-expression profiling in the primary tumor. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 6958-6963.	7.1	165
48	Two North American families with hereditary papillary renal carcinoma and identical novel mutations in the MET proto-oncogene. Cancer Research, 1998, 58, 1719-22.	0.9	146
49	Characterization of the VHL tumor suppressor gene product: localization, complex formation, and the effect of natural inactivating mutations.. Proceedings of the National Academy of Sciences of the United States of America, 1995, 92, 6459-6463.	7.1	144
50	Nuclear/cytoplasmic localization of the von Hippel-Lindau tumor suppressor gene product is determined by cell density.. Proceedings of the National Academy of Sciences of the United States of America, 1996, 93, 1770-1775.	7.1	137
51	Histopathology and Molecular Genetics of Multiple Cysts and Microcystic (Serous) Adenomas of the Pancreas in von Hippel-Lindau Patients. American Journal of Pathology, 2000, 157, 1615-1621.	3.8	136
52	Pheochromocytoma: evaluation, diagnosis, and treatment. World Journal of Urology, 1999, 17, 35-39.	2.2	133
53	VHL Gene Deletion and Enhanced VEGF Gene Expression Detected in the Stromal Cells of Retinal Angioma. JAMA Ophthalmology, 1999, 117, 625.	2.4	133
54	Regression of Metastatic Renal Cell Carcinoma After Cytoreductive Nephrectomy. Journal of Urology, 1993, 150, 463-466.	0.4	132

#	Article	IF	Citations
55	FAMILIAL RENAL ONCOCYTOMA: CLINICOPATHOLOGICAL STUDY OF 5 FAMILIES. Journal of Urology, 1998, 160, 335-340.	0.4	127
56	Molecular analysis of genetic changes in the origin and development of renal cell carcinoma. Cancer Research, 1991, 51, 1071-7.	0.9	127
57	Allelic deletions of the VHL gene detected in multiple microscopic clear cell renal lesions in von Hippel-Lindau disease patients. American Journal of Pathology, 1996, 149, 2089-94.	3.8	126
58	CYTOREDUCTIVE SURGERY BEFORE HIGH DOSE INTERLEUKIN-2 BASED THERAPY IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA. Journal of Urology, 1997, 158, 1675-1678.	0.4	120
59	INTERLEUKIN-2 BASED IMMUNOTHERAPY FOR METASTATIC RENAL CELL CARCINOMA WITH THE KIDNEY IN PLACE. Journal of Urology, 1999, 162, 43-45.	0.4	102
60	Renal cell carcinoma: Resection of solitary and multiple metastases. Annals of Thoracic Surgery, 1992, 54, 33-38.	1.3	99
61	Clinical and genetic analysis of patients with pancreatic neuroendocrine tumors associated with von Hippel-Lindau disease. Surgery, 2000, 128, 1022-1028.	1.9	98
62	Identification of the von Hippel-Lindau (VHL) gene. Its role in renal cancer. JAMA - Journal of the American Medical Association, 1995, 273, 564-70.	7.4	95
63	Preparative Cytoreductive Surgery in Patients with Metastatic Renal Cell Carcinoma Treated with Adoptive Immunotherapy with Interleukin-2 or Interleukin-2 Plus Lymphokine Activated Killer Cells. Journal of Urology, 1990, 144, 614-617.	0.4	90
64	Cytoreductive surgery prior to interleukin-2-based therapy in patients with metastatic renal cell carcinoma. Urology, 1993, 42, 250-257.	1.0	87
65	Molecular Profiling of Clinical Tissue Specimens. American Journal of Pathology, 2000, 156, 1109-1115.	3.8	84
66	Molecular and cellular characterization of human renal cell carcinoma cell lines. Cancer Research, 1992, 52, 348-56.	0.9	79
67	Molecular cloning of the von Hippel-Lindau tumor suppressor gene and its role in renal carcinoma. Biochimica Et Biophysica Acta: Reviews on Cancer, 1996, 1242, 201-210.	7.4	77
68	Immunotherapy with Interleukin-2 and Î± -Interferon in Patients with Metastatic Renal Cell Cancer with in Situ Primary Cancers: A Pilot Study. Journal of Urology, 1992, 147, 24-30.	0.4	67
69	Allelic deletion and mutation of the von Hippel-Lindau (VHL) tumor suppressor gene in pancreatic microcystic adenomas. American Journal of Pathology, 1997, 151, 951-6.	3.8	67
70	Imaging Features of Hereditary Papillary Renal Cancers. Journal of Computer Assisted Tomography, 1997, 21, 737-741.	0.9	63
71	Inactivation of the von Hippelâ€“Lindau tumor suppressor leads to selective expression of a human endogenous retrovirus in kidney cancer. Oncogene, 2011, 30, 4697-4706.	5.9	59
72	Loss of heterozygosity on the short arm of chromosomes 1 and 3 in sporadic pheochromocytoma and extra-adrenal paraganglioma. Human Pathology, 1997, 28, 411-415.	2.0	54

#	Article	IF	Citations
73	Molecular Profiling of Clinical Tissue Specimens. Journal of Molecular Diagnostics, 2000, 2, 60-66.	2.8	54
74	INTRAOPERATIVE ULTRASOUND DURING RENAL PARENCHYMAL SPARING SURGERY FOR HEREDITARY RENAL CANCERS:: A 10-YEAR EXPERIENCE. Journal of Urology, 2001, 165, 397-400.	0.4	54
75	HIF and fumarate hydratase in renal cancer. British Journal of Cancer, 2007, 96, 403-407.	6.4	54
76	Mapping the Von Hippel â€" Lindau disease tumour suppressor gene: identification of germline deletions by pulsed field gel electrophoresis. Human Molecular Genetics, 1993, 2, 879-882.	2.9	53
77	Prevalence of microscopic lesions in grossly normal renal parenchyma from patients with von Hippel-Lindau disease, sporadic renal cell carcinoma and no renal disease: clinical implications. Journal of Urology, 1995, 154, 2010-4; discussion 2014-5.	0.4	50
78	Fumarate hydratase enzyme activity in lymphoblastoid cells and fibroblasts of individuals in families with hereditary leiomyomatosis and renal cell cancer. Journal of Medical Genetics, 2006, 43, 755-762.	3.2	49
79	Loss of heterozygosity on the short arm of chromosome 3 in sporadic, von hippel-lindau disease-associated, and familial pheochromocytoma. Genes Chromosomes and Cancer, 1995, 13, 151-156.	2.8	48
80	Identification of a novel transcript up-regulated in a clinically aggressive prostate carcinoma. Urology, 1997, 50, 302-307.	1.0	47
81	Renal Toxicity of Interleukin-2 Administration in Patients With Metastatic Renal Cell Cancer: Effect of Pre-therapy Nephrectomy. Journal of Urology, 1989, 141, 499-502.	0.4	45
82	Chromosome imbalances in papillary renal cell carcinoma and first cytogenetic data of familial cases analyzed by comparative genomic hybridization. Cytogenetic and Genome Research, 1996, 75, 17-21.	1.1	44
83	Von Hippel-Lindau disease gene deletion detected in microdissected sporadic human colon carcinoma specimens. Human Pathology, 1996, 27, 152-156.	2.0	41
84	The genetic basis of renal epithelial tumors: advances in research and its impact on prognosis and therapy. Current Opinion in Urology, 2001, 11, 463-469.	1.8	33
85	Transcriptional Regulation of Phenylethanolamine N-Methyltransferase in Pheochromocytomas from Patients with von Hippel-Lindau Syndrome and Multiple Endocrine Neoplasia Type 2. Annals of the New York Academy of Sciences, 2006, 1073, 241-252.	3.8	24
86	INTRINSIC DRUG RESISTANCE IN PRIMARY AND METASTATIC RENAL CELL CARCINOMA. Journal of Urology, 1999, 162, 217-224.	0.4	23
87	International cancer seminars: a focus on kidney cancer. Annals of Oncology, 2016, 27, 1382-1385.	1.2	18
88	Partial adrenalectomy in patients with multiple adrenal tumors. Current Urology Reports, 2001, 2, 19-23.	2.2	12
89	Von Hippel-Lindau syndrome: hereditary cancer arising from inherited mutations of the VHL tumor suppressor gene. Cancer Treatment and Research, 1996, 88, 13-39.	0.5	12
90	Genetic Screening for von Hippel-Lindau Gene Mutations in Non-syndromic Pheochromocytoma: Low Prevalence and False-positives or Misdiagnosis Indicate a Need for Caution. Hormone and Metabolic Research, 2012, 44, 343-348.	1.5	11

#	Article	IF	Citations
91	Isolated perfusion of the kidney with tumor necrosis factor for localized renal-cell carcinoma. World Journal of Urology, 1996, 14, S2-7.	2.2	10
92	The Management of Isolated Renal Recurrence of Renal Cell Carcinoma Following Complete Response to Interleukin-2 Based Immunotherapy. Journal of Urology, 1993, 150, 176-178.	0.4	9
93	Interaction of von Hippel-Lindau tumor suppressor gene product with elongin. Methods in Enzymology, 1996, 274, 436-441.	1.0	7
94	Hereditary Papillary Renal Carcinoma: Pathology and Pathogenesis. , 1999, 128, 11-27.		6
95	Suramin inhibits bone resorption and reduces osteoblast number in a neonatal mouse calvarial bone resorption assay. Endocrinology, 1992, 131, 2263-2270.	2.8	5
96	Renal Cell Carcinoma. Journal of Urology, 1988, 139, 340-341.	0.4	4
97	Flow cytometric DNA analysis of interleukin-2 responsive renal cell carcinoma. Journal of Surgical Oncology, 1993, 53, 252-255.	1.7	4
98	Comorbid genetic diseases, von Hippel-Lindau disease and spinocerebellar ataxia type 2, confounding the diagnosis of cerebellar dysfunction in an adolescent. Clinical Neurology and Neurosurgery, 2001, 103, 216-219.	1.4	3
99	Molecular Genetics of Kidney Cancer: Implications for the Physician. Baylor University Medical Center Proceedings, 2000, 13, 368-371.	0.5	1
100	Molecular Analysis of the von Hippel-Lindau Disease Gene. Methods in Molecular Medicine, 2001, 53, 193-216.	0.8	1
101	Lymphangitic Retroperitoneal Carcinomatosis Occurring From Metastatic Sarcomatoid Chromophobe Renal Cell Carcinoma. Urology Case Reports, 2014, 2, 39-42.	0.3	1
102	This Month in Investigative Urology: Adoptive Immunotherapy of Genitourinary Tumors with Interleukin-2. Journal of Urology, 1988, 140, 838-839.	0.4	0
103	Prostate Cancer: Where are We Going?. Baylor University Medical Center Proceedings, 2000, 13, 366-367.	0.5	0
104	Comorbid VHL and SCA2 mutations in a large kindred: confounding diagnosis of neurological dysfunction caused by CNS VHL vascular tumours versus SCA2 atrophic neurodegeneration. Journal of Medical Genetics, 2002, 39, 37e-37.	3.2	0